The company’s final pricing represents a significant increase from its initial filing, which sought to offer 17.6 million shares at a range between $16 and $18. By pricing at the top of that window and increasing the volume of shares sold, Eikon has secured a more aggressive entry into the public markets. The stock will trade under the ticker symbol EIKN.

Capitalization and Market Position

Following the offering, Eikon will have approximately 57.2 million shares outstanding, according to the company's filing, assuming underwriters exercise their full option to purchase an additional 3.18 million shares. This share count gives the company an initial market capitalization exceeding $1 billion, placing the clinical-stage developer in a competitive position among its biotech peers.

Headquartered in Millbrae, California, Eikon focuses on applying advanced engineering to drug discovery. This debut marks a pivotal shift for the firm as it transitions from a private entity to a public biopharmaceutical player on the Nasdaq Global Select Market.